A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

In a yearlong investigation led by the International Consortium of Investigative Journalists, reporters from more than 37 ...

CytomX Therapeutics is testing CX-801 with Keytruda in a phase 1 trial for metastatic melanoma, focusing on safety and clinical activity. The trial is conducted at UCSF and the University of ...

Keytruda shows consistent efficacy and safety in advanced bladder carcinoma patients ineligible for platinum-based chemotherapy, with varying objective response rates and survival metrics across ...

By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...

By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, ...